Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental Vaccine-Like therapy targets Hard-to-Treat cancers

NCT ID NCT04853017

Disease control Sponsor: Elicio Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack cancer cells carrying specific KRAS mutations. The main goal was to check safety, and researchers also looked for reductions in tumor DNA in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ELI-002 (a combination of an immune-stimulating compound and cancer-targeting peptides)
What this could lead to
If successful, this could lead to a new immunotherapy option for people with certain KRAS-mutated cancers, potentially helping to keep the disease from coming back after standard treatment.
What could go wrong
This is a very early Phase 1 trial with only 25 participants, so it is too soon to know if the treatment works. The main goal was safety, not effectiveness, and many early-stage therapies do not move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

25 people

The number who actually took part.

Started

Oct 2021

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * KRAS/NRAS mutated (G12D or G12R) solid tumor * Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable * Screening CT is negative for recurrent disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Presence of tumor mutations where specific therapy is approved, and the patient is able to receive the approved therapy * Known brain metastases * Use of immunosuppressive drugs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bile duct cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bile duct cancer bile duct neoplasm cholangiocarcinoma colonic neoplasm colorectal cancer colorectal neoplasm gallbladder carcinoma gallbladder neoplasm neoplasm Neoplasm, Residual non-small cell lung carcinoma ovarian cancer pancreatic ductal adenocarcinoma rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bile duct cancer Cholangiocarcinoma Colorectal cancer Gallbladder carcinoma KRAS G12D KRAS G12R Minimal residual disease Non-small cell lung cancer NRAS G12D NRAS G12R Ovarian cancer Pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Northwell Health

    Lake Success, New York, 11042, United States

  • Tennessee Oncology - Centennial Clinic

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of California Los Angeles

    Los Angeles, California, 90095, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.